Agios Pharmaceuticals Inc to Review the Rise up Phase 2 Data and next Steps for the Phase 3 Portion of the Study Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Brian and team, congrats on the data today. Maybe I'll just start maybe for Ahmar and for Sarah. Just to help us understand at this time point and with at least the data that you're showing today just help put this into context with respect to how you're viewing mitapivat against other orals out there, other treatments and the standard of care, certainly, some detail that I respect that you're withholding into a larger medical conference, but any context you have there? Maybe a second question is just how that the VOCs at least the pain crisis in context, certainly a big focus and great to see the trend but how you see that sort of playing out as you look at this versus placebo? And then last question, Brian, for you. What inputs are you looking at in order to select that dose? And when would we be able to see the rationale there?

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Congrats on the update. Have you done any sensitivity analysis to look at what the responder rates would be at thresholds of maybe 1.5 or 2? And are you able to talk about the mean hemoglobin increase that you saw?

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Got it. And then what length of follow-up do you think is needed to see a static response in VOCs? And how is the Phase III portion powered to detect VOC reduction over 1 year?